. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: J Subst Abuse Treat. 2016 Sep 9;72:32–39. doi: 10.1016/j.jsat.2016.08.020

Table 1.

Participant demographics and relationships to variables of interest.

	Placebo group M (SD) or N (%) (n = 40)	L-DOPA group M (SD) or N (%) (n = 45)	Difference between groups
Sex
Female	5 (13%)	10 (22%)	χ² = 1.38
Race/Ethnicity
White	8 (2%)	7 (16%)	Fisher Exact = 0.0222
Black	26 (65%)	33 (73%)
Hispanic	5 (13%)	5 (11%)
Other	1 (3%)	0 (0%)
Baseline UDS
Positive	34 (85%)	38 (84%)	χ² = 0.01
Age	45 (9.2)	46 (7.9)	χ² = 0.21
Education	12 (1.6)	13 (1.5)	χ² = 3.85^*
Days using alcohol this month	10 (9.7)	7 (8.8)	χ² = 0.39
Years using alcohol	16 (10.7)	15 (15.2)	χ² = 0.92
Days using cocaine this month	16 (9.0)	15 (9.1)	χ² = 0.62
Years using cocaine	15 (7.1)	15 (8.4)	χ² = 0.08

Note: UDS = urine drug screen; L-DOPA = levodopa.

p < 0.05.